Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dehydrogenase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    262 result(s) found for: Dehydrogenase. Displaying page 10 of 14.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next»
    EudraCT Number: 2018-003775-35 Sponsor Protocol Number: SHP655-201 Start Date*: 2019-07-03
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficac...
    Medical condition: acquired thrombotic thrombocytopenic purpura (aTTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002153-11 Sponsor Protocol Number: GS-LHON-CLIN-06 Start Date*: 2018-02-12
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003229-27 Sponsor Protocol Number: ImPRESS Start Date*: 2019-06-04
    Sponsor Name:Oslo University Hospital
    Full Title: ImPRESS - Imaging Perfusion Restrictions from Extracellular Solid Stress - An open-label losartan study
    Medical condition: Patients with newly diagnosed or recurrent glioblastomas Patients with brain metastases from non-small-cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004403-14 Sponsor Protocol Number: BCX9930-203 Start Date*: 2021-11-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Noct...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) LT (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001469-18 Sponsor Protocol Number: CT2-04-17 Start Date*: 2019-04-17
    Sponsor Name:Dipartimento di Scienze della Vita e Biotecnologie dell'Università degli Studi di Ferrara
    Full Title: Treatment of beta-thalassemia patients with rapamycin (sirolimus): from pre-clinical research to a clinical trial
    Medical condition: Beta-thalassemia transfusion dependent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    20.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005005-17 Sponsor Protocol Number: R3918-PNH-2092 Start Date*: 2021-05-07
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-label, Two-arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients with Paroxysmal Nocturnal Hemoglo...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-003157-27 Sponsor Protocol Number: Sobi.PEGCET-201 Start Date*: 2021-12-17
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (...
    Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002727-11 Sponsor Protocol Number: CRO-2020-043 Start Date*: 2023-08-02
    Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO
    Full Title: Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study.
    Medical condition: Patients with locally advanced, potentially resectable, Middle-Distal Rectal Carcinoma, stage T3c-d N1-2, MRF + or T4N0-2, EMVI - / + (High-Risk)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007464 Carcinoma rectum LLT
    20.0 100000004864 10038052 Rectal carcinoma LLT
    20.0 100000004864 10007446 Carcinoma of rectum LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000331-63 Sponsor Protocol Number: HGB-210 Start Date*: 2021-02-09
    Sponsor Name: bluebird bio, Inc.
    Full Title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001305-23 Sponsor Protocol Number: 20190505 Start Date*: 2021-09-15
    Sponsor Name:Amgen
    Full Title: A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Medical condition: Metastatic Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000528-42 Sponsor Protocol Number: 0601 Start Date*: 2008-07-17
    Sponsor Name:Poniard Pharmaceuticals, Inc.
    Full Title: A Randomized, Controlled Phase III Trial of Picoplatin and Best Supportive Care (BSC) versus BSC Alone in Patients with Small Cell Lung Cancer (SCLC), Refractory or Progressive within Six Months of...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) LV (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005623-27 Sponsor Protocol Number: RM-131-009 Start Date*: 2015-04-08
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastropa...
    Medical condition: Vomiting symptoms in patient with moderate to severe diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004972-49 Sponsor Protocol Number: CLFG316X2202 Start Date*: 2016-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant ass...
    Medical condition: Transplant associated microangiopathy (TAM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10050444 Microangiopathy NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001516-30 Sponsor Protocol Number: GDX-44-007 Start Date*: Information not available in EudraCT
    Sponsor Name:GUERBET
    Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI.
    Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10029817 Nuclear magnetic resonance imaging brain PT
    21.1 10022891 - Investigations 10072232 Nuclear magnetic resonance imaging spinal PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Ongoing) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000147-98 Sponsor Protocol Number: 20060159 Start Date*: 2007-08-14
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double Blinded, Multi-Center Study 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metas...
    Medical condition: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003255-30 Sponsor Protocol Number: 20150291 Start Date*: 2017-10-04
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Trans...
    Medical condition: High-risk Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002971-12 Sponsor Protocol Number: IMCgp100-201 Start Date*: 2016-05-26
    Sponsor Name:Immunocore Limited
    Full Title: A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compa...
    Medical condition: Advanced Malignant Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000293-20 Sponsor Protocol Number: INCB18424-362 Start Date*: 2014-07-31
    Sponsor Name:Incyte Corporation
    Full Title: INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of ...
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed adenocarcinoma of the pancreas that is inoperable or metastatic.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001264-28 Sponsor Protocol Number: P2-IMU-838-COV Start Date*: 2020-05-28
    Sponsor Name:Immunic AG
    Full Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Ca...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) RO (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-003924-19 Sponsor Protocol Number: RVT-1401-2003 Start Date*: 2020-05-25
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia
    Medical condition: Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Completed) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 18:02:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA